ArticlePediatric nephrology (Berlin, Germany)2012
Rasburicase for hyperuricemia in hemolytic uremic syndrome.
Article in Pediatric nephrology (Berlin, Germany), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 20 citations in OpenAlex.
- Investigating the Role of Food-Derived Peptides in Hyperuricemia: From Mechanisms of Action to Structural Effects.Foods (Basel, Switzerland) · 2024Review
- Use of rasburicase to improve kidney function in children with hyperuricemia and acute kidney injury.Clinical and experimental nephrology · 2024Article
- Hyperuricemia: an unrecognized risk factor for kidney-related sequelae in children with hemolytic uremic syndrome.Pediatric nephrology (Berlin, Germany) · 2023Article
- "Disproportionate" hyperuricemia in children with hemolytic uremic syndrome (HUS): should we regard this as a "medical emergency"?Pediatric nephrology (Berlin, Germany) · 2020Article
- Rasburicase improves the outcome of acute kidney injury from typical hemolytic uremic syndrome.Pediatric nephrology (Berlin, Germany) · 2020Article
- Rasburicase in hemolytic uremic syndrome related to Shiga toxin-producing Escherichia coli: a report of nine cases.Pediatric nephrology (Berlin, Germany) · 2020Article
- Prevention and treatment of tumor lysis syndrome, and the efficacy and role of rasburicase.OncoTargets and therapy · 2017Review
- Cyanosis in a male Nigerian infant with acute kidney injury: answers.Pediatric nephrology (Berlin, Germany) · 2014Article
- Uric acid and the kidney.Pediatric nephrology (Berlin, Germany) · 2014Review
- Hyperuricemia in children with post-diarrheal hemolytic uremic syndrome.Pediatric nephrology (Berlin, Germany) · 2012Article
- Is it the right time to subject children with acute kidney injury to rasburicase trials?Pediatric nephrology (Berlin, Germany) · 2012Article
- Role of host xanthine oxidase in infection due to enteropathogenic and Shiga-toxigenic Escherichia coli.Gut microbesArticle
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute kidney injury (AKI) with elevated serum uric acid (UA) levels has been reported in patients with hemolytic uremic syndrome (HUS). AKI is thought to result from tubular obstruction by UA crystals. Inducing a diuresis may ameliorate the oligoanuria in such patients. We describe a child with HUS in whom reducing UA with fluids and rasburicase appeared to accelerate the recovery of renal function. CASE-DIAGNOSIS/TREATMENT: A 9-month-old Caucasian male infant presented with 6 days of diarrhea, 3 days of vomiting, and 24 h of oliguria. On admission, hemoglobin was 8.3 g/dL, platelet count 36,000/L, blood urea nitrogen 73 mg/dL, and serum creatinine (SCr) 2.7 mg/dL. Diarrhea-associated HUS was diagnosed. The day after admission, SCr was 2.9 mg/dL and UA 12.3 mg/dL. On hospital day 2, he received a dose of intravenous rasburicase 0.18 mg/kg, and less than 12 h later, the UA had fallen to 0.3 mg/dL. The SCr level also started to fall, and urine output progressively increased without the use of diuretics. Renal function continued to improve, and the UA level remained normal despite ongoing hemolysis requiring a second red blood cell transfusion on hospital day 5. The patient was discharged on hospital day 7 in good physical condition. Two months later, he was in good health, with a SCr level of 0.2 mg/dL and UA of 4.2 mg/dL.
conclusionsWe postulate that aggressive management of the high serum UA level with rasburicase and fluid hydration accelerated the recovery of our patient. Further studies are needed to determine the role of rasburicase in the treatment of hyperuricemia in patients with HUS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.